The findings were presented on March 1 at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS ... impact on factors such as the NLRP3 inflammasome, which could ...

which has just reported phase 1 results with its first two NLRP3 inhibitors, and ZyVersa Therapeutics with preclinical-stage candidate IC 100 that is being considered for multiple sclerosis.

Diet plays a pivotal role in influencing autoimmu n e diseases like multiple sclerosis (MS), inflammatory ... inflammatory signals by inhibiting the NLRP3 inflammasome, a protein complex involved ...

ZYIL1 is a novel oral small molecule NLRP3 inhibitor ... According to Rutgers researchers, the majority of people with multiple sclerosis (MS) choose oral medications to treat the chronic and ...

The NLRP3 inflammasome is implicated in a host ... in preclinical development but being eyed as a possible treatment for multiple sclerosis. Brian Hilberdink, Boehringer Ingelheim's new Head ...